title: Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
abstract: The proportions and activation status of T cells may influence responses to hepatitis C virus (HCV) and treatment outcome in patients receiving pegylated interferon (IFN)-alpha/ribavirin therapy. We confirmed that IFN-gamma enzyme-linked immunospot (ELISPOT) responses to HCV are poor in HCV patients and showed that responses to HCV and cytomegalovirus (CMV) antigens decrease during therapy. This was most apparent in patients with sustained virological response (SVR). Baseline frequencies of CD4+ effector memory (TEM) T cells were lower in SVR than non-SVR. Proportions of CD4+ and CD8+ TEM and terminally differentiated effector memory (TEMRA) T cells declined on therapy in SVR, as did proportions of Fas+ CD8+ TEMRA T cells. Baseline frequencies of programmed death (PD)-1-expressing CD4+ TEM and TEMRA T-cells were higher in SVR. Therapy increased percentages of PD-1+ CD4+ central memory (TCM) T cells and PD-1+ CD8+ TEM and TEMRA T cells in SVR. We conclude that successful therapy depletes circulating antigen-specific CD4+ T cell responses. This paralleled decreases in proportions of effector memory T cells and higher percentages of CD4+ TCM T cells expressing PD-1.
authors.affiliation: Department of Microbiology and Infectious Disease, Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital, School of Pathology and Laboratory Medicine, University of Western Australia, WA, Australia. silvialee@meddent.uwa.edu.au
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.forename: T
authors.initials: T
authors.lastname: Hammond
authors.forename: M W
authors.initials: MW
authors.lastname: Watson
authors.forename: J P
authors.initials: JP
authors.lastname: Flexman
authors.forename: W
authors.initials: W
authors.lastname: Cheng
authors.forename: S
authors.initials: S
authors.lastname: Fernandez
authors.forename: P
authors.initials: P
authors.lastname: Price
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000956:Antigens, Viral / Q000276:immunology; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D051017:Apoptosis Regulatory Proteins / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000737:chemistry / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry / Q000276:immunology; D003587:Cytomegalovirus / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D018936:Hepatitis C Antigens / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000378:metabolism; D007962:Leukocytes / Q000276:immunology*; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D061026:Programmed Cell Death 1 Receptor; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology*; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D000956:Antigens, Viral; D000998:Antiviral Agents; D051017:Apoptosis Regulatory Proteins; D018936:Hepatitis C Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007371:Interferon-gamma; C100416:peginterferon alfa-2a
references.citation: Viral Immunol. 2009 Feb;22(1):39-48
references.pmid: 19210227
references.citation: J Hepatol. 2008 Sep;49(3):329-38
references.pmid: 18644644
references.citation: Hepatology. 1996 Aug;24(2):289-93
references.pmid: 8690394
references.citation: J Exp Med. 1992 Jul 1;176(1):245-53
references.pmid: 1377224
references.citation: J Immunol. 2005 Dec 15;175(12):8415-23
references.pmid: 16339584
references.citation: Gastroenterology. 2002 Oct;123(4):1070-83
references.pmid: 12360469
references.citation: Hepatology. 2001 Jan;33(1):267-76
references.pmid: 11124845
references.citation: Science. 2003 Oct 24;302(5645):659-62
references.pmid: 14576438
references.citation: Blood. 2009 Jan 22;113(4):769-74
references.pmid: 18583570
references.citation: Antivir Ther. 2007;12(4):459-68
references.pmid: 17668554
references.citation: Hepatology. 2002 Sep;36(3):743-54
references.pmid: 12198669
references.citation: J Exp Med. 2000 May 1;191(9):1499-512
references.pmid: 10790425
references.citation: J Infect Dis. 2003 Nov 15;188(10):1533-6
references.pmid: 14624379
references.citation: J Exp Med. 2003 Jun 16;197(12):1645-55
references.pmid: 12810686
references.citation: Nature. 2005 Aug 18;436(7053):967-72
references.pmid: 16107837
references.citation: Clin Exp Immunol. 2006 Nov;146(2):270-7
references.pmid: 17034579
references.citation: Annu Rev Immunol. 2008;26:677-704
references.pmid: 18173375
references.citation: J Allergy Clin Immunol. 2005 Nov;116(5):949-59; quiz 960
references.pmid: 16275360
references.citation: Viral Immunol. 2001;14(2):169-79
references.pmid: 11398812
references.citation: J Infect Dis. 2009 Mar 15;199(6):819-28
references.pmid: 19434929
references.citation: J Hepatol. 2006 Mar;44(3):475-83
references.pmid: 16426698
references.citation: Annu Rev Immunol. 2002;20:551-79
references.pmid: 11861612
references.citation: J Clin Virol. 2004 Nov;31(3):227-34
references.pmid: 15465417
references.citation: J Immunol Methods. 2007 Jan 30;319(1-2):41-52
references.pmid: 17173927
references.citation: Viral Immunol. 2005;18(1):197-204
references.pmid: 15802964
references.citation: Clin Immunol Immunopathol. 1994 Dec;73(3):350-7
references.pmid: 7955564
references.citation: Clin Chem. 2002 Dec;48(12):2147-54
references.pmid: 12446470
references.citation: Eur J Immunol. 1998 Nov;28(11):3448-55
references.pmid: 9842887
references.citation: Hepatology. 2004 Nov;40(5):1062-71
references.pmid: 15486925
references.citation: HIV Med. 2003 Apr;4(2):120-6
references.pmid: 12702132
references.citation: Gut. 2006 Oct;55(10):1484-7
references.pmid: 16543291
references.citation: J Viral Hepat. 2008 Jan;15(1):2-11
references.pmid: 18088238
references.citation: Eur J Immunol. 2005 Jun;35(6):1681-91
references.pmid: 15902688
references.citation: J Exp Med. 2001 Nov 19;194(10):1395-406
references.pmid: 11714747
references.citation: Blood. 2003 Apr 1;101(7):2711-20
references.pmid: 12433688
references.citation: Immunity. 2005 Mar;22(3):329-41
references.pmid: 15780990
references.citation: J Hepatol. 2007 Nov;47(5):632-41
references.pmid: 17560677
references.citation: Antivir Ther. 2007;12(3):303-16
references.pmid: 17591020
references.citation: J Virol. 2007 Sep;81(17):9249-58
references.pmid: 17567698
references.citation: Clin Immunol. 2007 Apr;123(1):40-9
references.pmid: 17239662